Comment évaluer la réponse thérapeutique d’un gliome en pratique

Batchelor, 2007, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell, 11, 83, 10.1016/j.ccr.2006.11.021 Brandsma, 2008, Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas, Lancet Oncol, 9, 453, 10.1016/S1470-2045(08)70125-6 Brandsma, 2009, Pseudoprogression and pseudoresponse in the treatment of gliomas, Curr Opin Neurol, 22, 633, 10.1097/WCO.0b013e328332363e de Groot, 2010, Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice, Neuro Oncol, 12, 233, 10.1093/neuonc/nop027 Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, 27, 4733, 10.1200/JCO.2008.19.8721 Grand, 2005, Proton magnetic resonance spectroscopy (1H-MRS) for the diagnosis of brain tumors and the evaluation of treatment, Neurochirurgie, 51, 299, 10.1016/S0028-3770(05)83491-5 Henson, 2008, Brain tumor imaging in clinical trials, AJNR Am J Neuroradiol, 29, 419, 10.3174/ajnr.A0963 Kreisl, 2009, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, 27, 740, 10.1200/JCO.2008.16.3055 Norden, 2008, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence, Neurology, 70, 779, 10.1212/01.wnl.0000304121.57857.38 Quant, 2011, Response assessment in neuro-oncology, Curr Oncol Rep., 13, 50, 10.1007/s11912-010-0143-y Soffietti, 2010, Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force, Eur J Neurol, 17, 1124, 10.1111/j.1468-1331.2010.03151.x Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330 Taal, 2008, Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide, Cancer, 113, 405, 10.1002/cncr.23562 Wen, 2010, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working goup, J Clin Oncol, 28, 1963, 10.1200/JCO.2009.26.3541 Wen, 2010, Response assessment challenges in clinical trials of gliomas, Curr Oncol Rep, 12, 68, 10.1007/s11912-009-0078-3 Wong, 1999, Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials, J Clin Oncol, 17, 2572, 10.1200/JCO.1999.17.8.2572 Wyss, 2009, Early metabolic responses in temozolomide treated low-grade glioma patients, J Neurooncol, 95, 87, 10.1007/s11060-009-9896-2